ImmunoGenesis announces that two poster presentations on its lead development program, IMGS-001, will be presented at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022), November 8-12, 2022, in Boston, MA. The posters will be available on the ImmunoGenesis website following the conference.
Read moreNews
There is always something new at ImmunoGenesis. Stay on top of the latest.
Press Releases
ImmunoGenesis CEO James Barlow to Present on Company’s Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers at BIO CEO & Investor Conference
ImmunoGenesis announces that President and CEO James Barlow will present on the company and its multiple immune-oncology therapeutic development programs targeting immune-excluded cold cancers at the upcoming 2022 BIO CEO & Investor Conference.
Read more
ImmunoGenesis CEO James Barlow to Present on Company’s Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers at Biotech Showcase
ImmunoGenesis announces that CEO James Barlow will present about the company and its multiple immune-oncology therapeutic development programs at Biotech Showcase 2022 on January 10 at 2:30 PM PST.
Read moreKey Publications
Development of IMGS-001, a novel anti–PD-L1/PD-L2 dual-specific, multifunctional antibody, to treat immune-excluded tumors.
C Gagliardi, A Salameh, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.
Preclinical characterization of IMGS-001, a dual-antagonist anti–PD-L1 and PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade.
A Salameh, C Gagliardi, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack, AL, Spartz, EJ, Raynor, JF, Wang, I, Olson, M, Stromnes, IM. Cell Reports. 2019.
Genomic biomarkers in relation to PD-1 checkpoint blockade response.
Seiwert, TY, Cristescu, R, Kaufman, DR, et al. Journal of Clinical Oncology. 2018.
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley, JH, Gibson, C, Yu, N, Moon, C, Murphy, E, McClanahan, T, et al. Clinical Cancer Research. 2017.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Curran, MA, Montalvo, W, Yagita, H, Allison, JP. PNAS. 2010.
Upcoming events
There are no upcoming events scheduled at this time. Sign up to receive notices about upcoming events and press releases.
Excited about what you see?
Learn more